Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2019

CLL MM LBA Rundown MRD Transplant RWD MPN MDS Trials Lymphoma CAR-T Press Briefs AML ALL

CLL

View all
4:08
MURANO update: sustained benefit for time-limited VenR & biomarkers for response in CLL
Arnon Kater • 7 Dec 2019
2:04
CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
Constantine Tam • 10 Dec 2019

Multiple Myeloma

View all
1:15
Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM
Irene Ghobrial • 6 Dec 2019
2:18
Blood screening for MGUS: preventing progression with PROMISE
Irene Ghobrial • 6 Dec 2019

MRD Updates

View all
2:04
CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
Constantine Tam • 10 Dec 2019
4:41
MRD-based response-adapted consolidation in NDMM post-transplant
Luciano Costa • 10 Dec 2019

Transplant

View all
5:16
FLAMSU-Bu conditioning doesn’t improve outcome in AML/MDS irrespective of pre-transplant MRD status
Charles Craddock • 6 Dec 2019
2:59
Tandem transplantation in NDMM: auto-auto vs. auto-allo analysis
Luciano Costa • 7 Dec 2019

MPN

View all
4:24
Luspatercept benefits MF-associated anemia
Aaron Gerds • 8 Dec 2019
2:05
Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
Jean-Jacques Kiladjian • 8 Dec 2019

MDS

View all
5:16
FLAMSU-Bu conditioning doesn’t improve outcome in AML/MDS irrespective of pre-transplant MRD status
Charles Craddock • 6 Dec 2019
1:22
MDS updates from ASH 2019
David Steensma • 7 Dec 2019

Lymphoma

View all
8:54
FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Bahram Valamehr • 7 Dec 2019
2:25
Primary analysis of Pola-G-Len: favorable findings for R/R follicular lymphoma
Catherine Diefenbach • 7 Dec 2019

CAR-T

View all
3:25
Allogeneic CAR-T technology
Bijal Shah • 6 Dec 2019
8:54
FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Bahram Valamehr • 7 Dec 2019

AML

View all
2:07
Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan • 6 Dec 2019
5:16
FLAMSU-Bu conditioning doesn’t improve outcome in AML/MDS irrespective of pre-transplant MRD status
Charles Craddock • 6 Dec 2019

ALL

View all
3:25
Allogeneic CAR-T technology
Bijal Shah • 6 Dec 2019
3:23
First-in-human trial of a BCMA-CD19 compound CAR in B-ALL
Fang Liu • 7 Dec 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals